✓ Translated by DotMD AI Clinical Council Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40638782 ↗

Phase III Randomized Trial: The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study (N = 34)

Original Paper Title: “The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 34
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Vilobelimab therapy provides a cost-effective option to treat severely ill, mechanically ventilated patients with COVID-19 with prior and/or concomitant treatment with immunomodulators at a value well below the commonly accepted willingness-to-pay threshold of $50,000/QALY.
  • Study Design & Sample: Phase III Randomized Trial published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (N = 34 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2026), this phase iii randomized trial evaluating 34 human participants investigated: The anti-C5a complement factor blocker vilobelimab (Gohibic) is authorized for emergency use by the US Food and Drug Administration for the treatment of hospitalized adults with COVID-19 when initiated within 48 hours of starting invasive mechanical ventilation or extracorporeal membrane oxygenation. Key clinical takeaway: Vilobelimab therapy provides a cost-effective option to treat severely ill, mechanically ventilated patients with COVID-19 with...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026-01-27; N = 34; Rigor 82/100): Vilobelimab therapy provides a cost-effective option to treat severely ill, mechanically ventilated patients with COVID-19 with prior and/or concomitant treatment with immunomodulators at a value well below the commonly accepted willingness-to-pay threshold of $50,000/QALY.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: artificial-tears-polyvinyl-alcohol-povidone → Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Rx: bio-combination-28-schuessler-salts → Condition: osteomyelitis-tuberculosis → Condition: chronic-infection →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40638782: Phase III Randomized Trial: The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study (N = 34)

3 of 3 Free Questions Remaining